KR20120100913A - 아세틸콜린 수용체에 관련된 질환의 치료를 위한 축합 아진 - 유도체 - Google Patents
아세틸콜린 수용체에 관련된 질환의 치료를 위한 축합 아진 - 유도체 Download PDFInfo
- Publication number
- KR20120100913A KR20120100913A KR1020127009340A KR20127009340A KR20120100913A KR 20120100913 A KR20120100913 A KR 20120100913A KR 1020127009340 A KR1020127009340 A KR 1020127009340A KR 20127009340 A KR20127009340 A KR 20127009340A KR 20120100913 A KR20120100913 A KR 20120100913A
- Authority
- KR
- South Korea
- Prior art keywords
- diazabicyclo
- methyl
- nonan
- alkyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CC(C)NC(C*C(c1c(*)ccc(F)c1)=O)=O Chemical compound CC(C)NC(C*C(c1c(*)ccc(F)c1)=O)=O 0.000 description 4
- GUPLUDGNBXNASI-UHFFFAOYSA-N CC(C)(CN(C(c1cc(Cl)ccc1F)=Nc(cc1)c2cc1N1C(CC3)CCN3CC1)C2=O)CO Chemical compound CC(C)(CN(C(c1cc(Cl)ccc1F)=Nc(cc1)c2cc1N1C(CC3)CCN3CC1)C2=O)CO GUPLUDGNBXNASI-UHFFFAOYSA-N 0.000 description 1
- CITUJCDCMDHNEP-UHFFFAOYSA-N CC(C)NC(CN(C(C1CCCCC1)=Nc(cc1)c2cc1N1C(CC3)CCN3CC1)C2=O)=O Chemical compound CC(C)NC(CN(C(C1CCCCC1)=Nc(cc1)c2cc1N1C(CC3)CCN3CC1)C2=O)=O CITUJCDCMDHNEP-UHFFFAOYSA-N 0.000 description 1
- QUBKQLVWKZSYOC-UHFFFAOYSA-N CC(C)NC(CN(C(c1cc(F)cc(F)c1)=Nc(cc1)c2cc1N1C(CC3)CCN3CC1)C2=O)=O Chemical compound CC(C)NC(CN(C(c1cc(F)cc(F)c1)=Nc(cc1)c2cc1N1C(CC3)CCN3CC1)C2=O)=O QUBKQLVWKZSYOC-UHFFFAOYSA-N 0.000 description 1
- KSLDDCLRYOABGF-UHFFFAOYSA-N CC(C)NC(CN(C(c1ccccc1)=Nc(cc1)c2cc1N1C(CC3)CCN3CC1)C2=O)=O Chemical compound CC(C)NC(CN(C(c1ccccc1)=Nc(cc1)c2cc1N1C(CC3)CCN3CC1)C2=O)=O KSLDDCLRYOABGF-UHFFFAOYSA-N 0.000 description 1
- GDYFMOROHDHJMV-UHFFFAOYSA-N CC(C)NC(CN(C(c1ccccc1)=Nc(cc1)c2cc1N1CC(CN(C3)C(OC(C)(C)C)=O)C3C1)C2=O)=O Chemical compound CC(C)NC(CN(C(c1ccccc1)=Nc(cc1)c2cc1N1CC(CN(C3)C(OC(C)(C)C)=O)C3C1)C2=O)=O GDYFMOROHDHJMV-UHFFFAOYSA-N 0.000 description 1
- CIUSAKIVYAVQKY-UHFFFAOYSA-N CC(C)NC(CN(C(c1ccccc1)=Nc(cc1)c2cc1N1CC(CNC3)C3C1)C2=O)=O Chemical compound CC(C)NC(CN(C(c1ccccc1)=Nc(cc1)c2cc1N1CC(CNC3)C3C1)C2=O)=O CIUSAKIVYAVQKY-UHFFFAOYSA-N 0.000 description 1
- RKDDUWNJMDSYLK-UHFFFAOYSA-N CC(C)NC(CN(C(c1ccccc1F)=Nc(cc1)c2cc1N1C(CC3)CCN3CC1)C2=O)=O Chemical compound CC(C)NC(CN(C(c1ccccc1F)=Nc(cc1)c2cc1N1C(CC3)CCN3CC1)C2=O)=O RKDDUWNJMDSYLK-UHFFFAOYSA-N 0.000 description 1
- LMHHIAMMWMTQKO-UHFFFAOYSA-N CC(C)NC(CN(C=Nc(cc1)c2cc1N1CC(CN(C3)C(OC(C)(C)C)=O)C3C1)C2=O)=O Chemical compound CC(C)NC(CN(C=Nc(cc1)c2cc1N1CC(CN(C3)C(OC(C)(C)C)=O)C3C1)C2=O)=O LMHHIAMMWMTQKO-UHFFFAOYSA-N 0.000 description 1
- VGAMLXPQIKJIRV-UHFFFAOYSA-N CCC(N1C2CCC2)=Nc(ccc(N2C(CC3)CCN3CC2)c2)c2C1=O Chemical compound CCC(N1C2CCC2)=Nc(ccc(N2C(CC3)CCN3CC2)c2)c2C1=O VGAMLXPQIKJIRV-UHFFFAOYSA-N 0.000 description 1
- SOEPRDVVUFTACN-UHFFFAOYSA-N CCC(N1CC(N(C)C)=O)=Nc(ccc(N2C(CC3)CCN3CC2)c2)c2C1=O Chemical compound CCC(N1CC(N(C)C)=O)=Nc(ccc(N2C(CC3)CCN3CC2)c2)c2C1=O SOEPRDVVUFTACN-UHFFFAOYSA-N 0.000 description 1
- NKXSDZNKLCXPFA-UHFFFAOYSA-N CN(C(c1cc(C#N)ccc1)=Nc1c2ccc(N3C(CC4)CCN4CC3)c1)C2=O Chemical compound CN(C(c1cc(C#N)ccc1)=Nc1c2ccc(N3C(CC4)CCN4CC3)c1)C2=O NKXSDZNKLCXPFA-UHFFFAOYSA-N 0.000 description 1
- PPHIAYQNEAQCMX-UHFFFAOYSA-N CN(C(c1cc(Cl)ccc1)=Nc1c2cc(N3C(CC4)CCN4CC3)nc1)C2=O Chemical compound CN(C(c1cc(Cl)ccc1)=Nc1c2cc(N3C(CC4)CCN4CC3)nc1)C2=O PPHIAYQNEAQCMX-UHFFFAOYSA-N 0.000 description 1
- YFMQERMVMZKDCJ-UHFFFAOYSA-N CN(C(c1ccncc1)=Nc(cc1)c2cc1N1C(CC3)CCN3CC1)C2=O Chemical compound CN(C(c1ccncc1)=Nc(cc1)c2cc1N1C(CC3)CCN3CC1)C2=O YFMQERMVMZKDCJ-UHFFFAOYSA-N 0.000 description 1
- DNFFAFCULSITDH-UHFFFAOYSA-N CN(C(c1cnc[s]1)=Nc(cc1)c2cc1N1C(CC3)CCN3CC1)C2=O Chemical compound CN(C(c1cnc[s]1)=Nc(cc1)c2cc1N1C(CC3)CCN3CC1)C2=O DNFFAFCULSITDH-UHFFFAOYSA-N 0.000 description 1
- TZEGGLAQRXWSCY-UHFFFAOYSA-N CN(C1)CC2C1CN(C)C2 Chemical compound CN(C1)CC2C1CN(C)C2 TZEGGLAQRXWSCY-UHFFFAOYSA-N 0.000 description 1
- WSGVYRVTJRTQIQ-GJZGRUSLSA-N CN(C[C@@H]1C2)[C@@H]2CN1c(cc1)cc2c1N=C(c1cc(F)ccc1F)N(C)C2=O Chemical compound CN(C[C@@H]1C2)[C@@H]2CN1c(cc1)cc2c1N=C(c1cc(F)ccc1F)N(C)C2=O WSGVYRVTJRTQIQ-GJZGRUSLSA-N 0.000 description 1
- NRGUSJXTCUQTBB-RYUDHWBXSA-N CN(C[C@@H]1C2)[C@@H]2CN1c(cc1)cc2c1N=CN(C)C2=O Chemical compound CN(C[C@@H]1C2)[C@@H]2CN1c(cc1)cc2c1N=CN(C)C2=O NRGUSJXTCUQTBB-RYUDHWBXSA-N 0.000 description 1
- CMGDFEIKBFFGLS-BQBZGAKWSA-N CN1[C@@H](C2)CN(C)[C@@H]2C1 Chemical compound CN1[C@@H](C2)CN(C)[C@@H]2C1 CMGDFEIKBFFGLS-BQBZGAKWSA-N 0.000 description 1
- SRWDHJYCKZRAJU-UHFFFAOYSA-N COC1C(CC2)CCN2C1 Chemical compound COC1C(CC2)CCN2C1 SRWDHJYCKZRAJU-UHFFFAOYSA-N 0.000 description 1
- LOQXPUJLHUJHPJ-UHFFFAOYSA-N COCCN(C(C1CC1)=Nc(cc1)c2cc1N1C(CC3)CCN3CC1)C2=O Chemical compound COCCN(C(C1CC1)=Nc(cc1)c2cc1N1C(CC3)CCN3CC1)C2=O LOQXPUJLHUJHPJ-UHFFFAOYSA-N 0.000 description 1
- RIJGJDHIZJRUAZ-UHFFFAOYSA-N Cc1cc(C(N2CC3(CO)CCC3)=Nc(ccc(N3C(CC4)CCN4CC3)c3)c3C2=O)ccc1 Chemical compound Cc1cc(C(N2CC3(CO)CCC3)=Nc(ccc(N3C(CC4)CCN4CC3)c3)c3C2=O)ccc1 RIJGJDHIZJRUAZ-UHFFFAOYSA-N 0.000 description 1
- LSAYLIOEQNLKRY-UHFFFAOYSA-N Cc1cncc(C(N2C)=Nc(ccc(N3C(CC4)CCN4CC3)c3)c3C2=O)c1 Chemical compound Cc1cncc(C(N2C)=Nc(ccc(N3C(CC4)CCN4CC3)c3)c3C2=O)c1 LSAYLIOEQNLKRY-UHFFFAOYSA-N 0.000 description 1
- KBUWZOJACCKYCI-UHFFFAOYSA-N Cc1nc(C(N2CC3(CO)CCC3)=Nc(ccc(N3C(CC4)CCN4CC3)c3)c3C2=O)ccc1 Chemical compound Cc1nc(C(N2CC3(CO)CCC3)=Nc(ccc(N3C(CC4)CCN4CC3)c3)c3C2=O)ccc1 KBUWZOJACCKYCI-UHFFFAOYSA-N 0.000 description 1
- CVFYVFHDOVOTOM-UHFFFAOYSA-N OCC1(CN(C(C2CC2)=Nc(cc2)c3cc2N2C(CC4)CCN4CC2)C3=O)CCC1 Chemical compound OCC1(CN(C(C2CC2)=Nc(cc2)c3cc2N2C(CC4)CCN4CC2)C3=O)CCC1 CVFYVFHDOVOTOM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25110109P | 2009-10-13 | 2009-10-13 | |
| EP09172872 | 2009-10-13 | ||
| EP09172872.5 | 2009-10-13 | ||
| US61/251,101 | 2009-10-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20120100913A true KR20120100913A (ko) | 2012-09-12 |
Family
ID=42040651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127009340A Withdrawn KR20120100913A (ko) | 2009-10-13 | 2010-10-11 | 아세틸콜린 수용체에 관련된 질환의 치료를 위한 축합 아진 - 유도체 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8841289B2 (enExample) |
| EP (1) | EP2488520B1 (enExample) |
| JP (1) | JP2013507417A (enExample) |
| KR (1) | KR20120100913A (enExample) |
| CN (1) | CN102666540A (enExample) |
| AU (1) | AU2010305825A1 (enExample) |
| BR (1) | BR112012008518A2 (enExample) |
| CA (1) | CA2776835A1 (enExample) |
| IN (1) | IN2012DN02968A (enExample) |
| MX (1) | MX2012004289A (enExample) |
| RU (1) | RU2012119488A (enExample) |
| WO (1) | WO2011045258A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2563232T3 (es) | 2011-07-29 | 2016-03-11 | Taisho Pharmaceutical Co., Ltd. | Compuesto de amidina o sal del mismo |
| WO2013132253A1 (en) | 2012-03-07 | 2013-09-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| US20150164858A1 (en) * | 2012-05-22 | 2015-06-18 | King Abdullah University Of Science And Technology | Combination comprising parthenolide for use in the treatment of alzheimer's disease and other neurodegenerative disorders |
| EP3044221B1 (en) | 2013-09-11 | 2018-02-21 | Institute of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| EP3191459A1 (en) | 2014-09-05 | 2017-07-19 | AbbVie Deutschland GmbH & Co. KG | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases |
| EP3623371A1 (en) | 2014-12-16 | 2020-03-18 | Axovant Sciences GmbH | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶 |
| HK1248222A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 噻吩并嘧啶酮作为泛素特异性蛋白酶7抑制剂 |
| HK1248221A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 异噻唑啉酮类,吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂 |
| HK1248220A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂 |
| CN106146410B (zh) * | 2015-04-03 | 2018-10-12 | 中南大学 | 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途 |
| CN106279211B (zh) * | 2015-06-03 | 2020-09-15 | 北京大学 | 一种噻唑并嘧啶酮化合物及其制备方法和应用 |
| CA2988968A1 (en) | 2015-06-10 | 2016-12-15 | Forum Pharmaceuticals, Inc. | Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors |
| WO2017027600A1 (en) | 2015-08-12 | 2017-02-16 | Forum Pharmaceuticals, Inc. | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS |
| US10500205B2 (en) | 2015-12-09 | 2019-12-10 | Cadent Therapeutics, Inc. | Thienopyrimidinone NMDA receptor modulators and uses thereof |
| ES2821010T3 (es) | 2015-12-09 | 2021-04-23 | Cadent Therapeutics Inc | Moduladores heteroaromáticos del receptor NMDA y usos de los mismos |
| CA3047403A1 (en) | 2016-12-22 | 2018-06-28 | Cadent Therapeutics, Inc. | Nmda receptor modulators and uses thereof |
| CA3105174A1 (en) * | 2018-06-27 | 2020-01-02 | Reborna Biosciences, Inc. | Prophylactic or therapeutic agent for spinal muscular atrophy |
| HU231414B1 (hu) | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Tiadiazin származékok |
| CA3102326A1 (en) | 2018-07-26 | 2020-01-30 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4 |
| CA3108519A1 (en) | 2018-08-03 | 2020-04-30 | Cadent Therapeutics, Inc. | Heteroaromatic nmda receptor modulators and uses thereof |
| WO2021198191A1 (en) | 2020-03-30 | 2021-10-07 | Enyo Pharma | Quinazolinone derivatives and uses thereof for treating a cancer |
| WO2021198188A1 (en) | 2020-03-30 | 2021-10-07 | Enyo Pharma | Quinazolinone derivatives and uses thereof for treating a cancer |
| EP4204418A1 (en) | 2020-08-28 | 2023-07-05 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| CN112898290B (zh) * | 2021-01-29 | 2022-08-05 | 中南大学 | 异噁唑甲酰胺基-4(3h)-喹唑啉酮衍生物及其合成方法和用途 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| TW202539670A (zh) * | 2024-02-23 | 2025-10-16 | 大陸商海思科醫藥集團股份有限公司 | Braf抑制劑的製備方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| JP2005504730A (ja) * | 2001-04-20 | 2005-02-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Gsk−3インヒビターとして有用な組成物 |
| WO2003062235A1 (en) | 2002-01-17 | 2003-07-31 | Eli Lilly And Company | Modulators of acetylcholine receptors |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| TW200536830A (en) * | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| PT1910333E (pt) * | 2005-07-26 | 2013-08-01 | Sanofi Sa | Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase |
| CN101600698B (zh) | 2006-09-11 | 2012-01-11 | 欧加农股份有限公司;药典有限责任公司 | 喹唑啉酮和异喹啉酮乙酰胺衍生物 |
| JP5313919B2 (ja) * | 2006-12-27 | 2013-10-09 | サノフイ | 新規な置換イソキノリン及びイソキノリノン誘導体 |
| JP2010229035A (ja) * | 2007-08-01 | 2010-10-14 | Taisho Pharmaceutical Co Ltd | ピリドピリミジン−4−オン誘導体 |
| BRPI0820259A2 (pt) * | 2007-11-14 | 2015-06-16 | Neurosearch As | Derivado de 1,4-diaza-biciclo[3.2.2] nonil pirimidina, composição farmacêutica, uso do derivado de 1,4-diaza-biciclo[3.2.2] nonil pirimidina, e, método de tratamento, prevenção ou alívio de uma doença ou uma desordem ou uma condição de um corpo de animal vivo |
| WO2009107236A1 (ja) | 2008-02-29 | 2009-09-03 | テクノコアインターナショナル株式会社 | パック電池の充電装置及びパック電池の品質判定装置 |
-
2010
- 2010-10-11 KR KR1020127009340A patent/KR20120100913A/ko not_active Withdrawn
- 2010-10-11 MX MX2012004289A patent/MX2012004289A/es not_active Application Discontinuation
- 2010-10-11 CA CA2776835A patent/CA2776835A1/en not_active Abandoned
- 2010-10-11 IN IN2968DEN2012 patent/IN2012DN02968A/en unknown
- 2010-10-11 WO PCT/EP2010/065160 patent/WO2011045258A1/en not_active Ceased
- 2010-10-11 JP JP2012533593A patent/JP2013507417A/ja active Pending
- 2010-10-11 US US13/501,587 patent/US8841289B2/en active Active
- 2010-10-11 EP EP10771062.6A patent/EP2488520B1/en active Active
- 2010-10-11 RU RU2012119488/04A patent/RU2012119488A/ru unknown
- 2010-10-11 AU AU2010305825A patent/AU2010305825A1/en not_active Abandoned
- 2010-10-11 BR BR112012008518A patent/BR112012008518A2/pt not_active Application Discontinuation
- 2010-10-11 CN CN2010800465507A patent/CN102666540A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2488520A1 (en) | 2012-08-22 |
| WO2011045258A1 (en) | 2011-04-21 |
| AU2010305825A1 (en) | 2012-04-19 |
| JP2013507417A (ja) | 2013-03-04 |
| CN102666540A (zh) | 2012-09-12 |
| US8841289B2 (en) | 2014-09-23 |
| BR112012008518A2 (pt) | 2016-04-05 |
| MX2012004289A (es) | 2012-06-12 |
| CA2776835A1 (en) | 2011-04-21 |
| US20120208796A1 (en) | 2012-08-16 |
| EP2488520B1 (en) | 2015-09-02 |
| IN2012DN02968A (enExample) | 2015-07-31 |
| RU2012119488A (ru) | 2013-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2488520B1 (en) | Condensed azine-derivatives for the treatment of diseases related to the acetylcholine receptor | |
| CN113061132B (zh) | 一类稠环内酰胺类化合物、制备方法和用途 | |
| CN116332948A (zh) | 一种含氮四环化合物及其制备方法和药用用途 | |
| DK2300478T3 (en) | 1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-ONDERIVATIVER and their use as modulators PDE9A. | |
| JP6673920B2 (ja) | Parg阻害化合物 | |
| EP2057141B1 (en) | Pyrimidone compounds as gsk-3 inhibitors | |
| JP6800885B2 (ja) | イミダゾピラジン及びピラゾロピリミジン、並びにampa受容体調節物質としてのこれらの使用 | |
| WO2014060112A1 (en) | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors | |
| AU2022420827A1 (en) | Compounds and use thereof as hdac6 inhibitors | |
| CA2944475A1 (en) | Bicyclic-fused heteroaryl or aryl compounds | |
| CA2699384A1 (en) | Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists | |
| JP7801084B2 (ja) | Egfr阻害剤としてのインドリン化合物及び誘導体 | |
| JP2022547729A (ja) | 自己免疫疾患を治療するためのピペリジニルアミン化合物 | |
| RS63661B1 (sr) | Piridopirimidini kao inhibitori histaminskog h4-receptora | |
| WO2009043884A1 (en) | Azabicyclo [3. 1. 0] hexyl derivatives as modulators of dopamine d3 receptors | |
| WO2024261329A1 (en) | Heteroaryl-amine compounds and use thereof as hdac6 inhibitors | |
| MX2010011136A (es) | Derivados de pirrolo [2,3-d] pirimidin-2-il-amina como inhibidores pkc-theta. | |
| WO2026027696A1 (en) | Thiomethyl carbonyl compounds and use thereof as hdac6 inhibitors | |
| AU2006314136A1 (en) | Substituted bicyclic pyrimidone derivatives | |
| HK1149549B (en) | 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20120412 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20130530 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |